HomeNTRA • NASDAQ
add
Natera Inc
Previous close
$108.50
Day range
$106.40 - $108.75
Year range
$36.90 - $108.75
Market cap
13.01B USD
Avg Volume
1.28M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 367.74M | 52.11% |
Operating expense | 282.92M | 21.98% |
Net income | -67.60M | 50.63% |
Net profit margin | -18.38 | 67.55% |
Earnings per share | -0.56 | 54.47% |
EBITDA | -67.25M | 49.52% |
Effective tax rate | -0.64% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 882.94M | 8.73% |
Total assets | 1.47B | 11.32% |
Total liabilities | 674.09M | 0.87% |
Total equity | 794.11M | — |
Shares outstanding | 122.80M | — |
Price to book | 16.69 | — |
Return on assets | -12.77% | — |
Return on capital | -15.22% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -67.60M | 50.63% |
Cash from operations | 27.00M | 133.29% |
Cash from investing | 138.26M | 771.17% |
Cash from financing | 6.47M | 181.01% |
Net change in cash | 171.72M | 372.85% |
Free cash flow | -7.96M | 89.94% |
About
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
3,288
